profit from every $100 of sales.
$0$100
OmniAb
$0.39+129.35% today
+132.1% in 1 year
1-year low $0.041-year high $0.39
Trading close to its highest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
OmniAb vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| OmniAb | No profit yet | ||
 Vertex Pharmaceuticals | 34.8× · Expensive | ||
 Regeneron Pharmaceuticals | 21.8× · Fair price | ||
 Moderna | No profit yet | ||
 CSL | 22.3× · Fair price |
AI analysis
An AI analyst reads OmniAb's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisNo annual statements on file yet.
Valuation
- –
- –
- –
- 1.1×
- 9.0×
- –
- –
- -224.3%
- -19.4%
- 0.0%
Profitability
- 35.5%
- -200.3%
- -187.7%
- -121.5%
- -20.4%
- -14.9%
- -20.3%
- -18.5%
- -20.7%
- 154.8%
Growth
- −14.4%
- –
- +10.9%
- –
- −0.3%
Financial health
- 0.3×
- 0.07
- 6.7%
- –
- 4.80
- 4.80
- 0.10
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 20%of 952
Bottom 6%of 870
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 7, 2026 | -0.06 | -0.10 | +42.5% |
| Mar 4, 2026 | -0.11 | -0.09 | −25.0% |
| Nov 4, 2025 | -0.14 | -0.14 | −4.6% |
| Aug 6, 2025 | -0.15 | -0.15 | −0.5% |
| May 8, 2025 | -0.17 | -0.16 | −6.1% |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
1/7Passes 1 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
24No pass
Benjamin Graham
65Pass
Philip Fisher
36No pass
Peter Lynch
28No pass
Joel Greenblatt
0No pass
Charlie Munger
32No pass
Terry Smith
23No pass
Questions about OmniAb
Is OmniAb a good stock to buy?
A business with weak numbers that is not profitable yet. 1 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the OmniAb AI analysis
What does OmniAb do?
OmniAb, Inc., a biotechnology company, provides therapeutic antibody discovery technologies in the United States. It is in Biotechnology.
Does OmniAb pay a dividend?
No. OmniAb does not pay a dividend at the moment.
How has OmniAb stock done over the past year?
Up 132.1% over the past twelve months, to $0.39. It traded between $0.04 and $0.39, close to its high.
Who are OmniAb's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Moderna and CSL. The peers table on this page compares their profit, growth and price with OmniAb's.
Prices: daily closes to Oct 28, 2026. Fundamentals: company reports via invest-like data.